Senti Biosciences (SNTI) Cash & Equivalents (2021 - 2025)

Senti Biosciences has reported Cash & Equivalents for 5 years, with the latest figure at $16.4 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 65.99% year-over-year to $16.4 million; the trailing twelve-month figure through Dec 2025 stood at $16.4 million (down 65.99% YoY), and the FY2025 full-year result was $16.4 million, down 65.99% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $16.4 million, up from $12.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $139.8 million in Q2 2022, with the low at $10.5 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $46.8 million, with a median of $36.8 million recorded in 2023.
• Year-over-year, Cash & Equivalents surged 68.55% in 2022 and sank 73.71% in 2023.
• Tracing SNTI's Cash & Equivalents over 5 years: stood at $56.0 million in 2021, then increased by 2.83% to $57.6 million in 2022, then plunged by 37.7% to $35.9 million in 2023, then jumped by 34.48% to $48.3 million in 2024, then plunged by 65.99% to $16.4 million in 2025.
• The last three Cash & Equivalents figures came in at $16.4 million (Q4 2025), $12.2 million (Q3 2025), and $21.6 million (Q2 2025), per Business Quant data.

Peer Comparison